TASK DEFINITION: Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
PROBLEM: Paragraph: Two people who had travelled from Congo died in Uganda last week, the World Health Organization said. A three-year-old boy who was sent back to Congo after testing positive for the disease died at the weekend, Congo’s health ministry said. At least another 1,411 people have died in Congo since August in the second worst outbreak of the disease on record. “Happy to inform you all that we got clearance from both Uganda National Council for Science and Technology and National Drug Authority to bring in the Therapeutic treatment for #Ebola patients in the country,” Uganda’s Health Minister, Jane Ruth Aceng, said on Twitter. The treatments approved for shipment to Uganda were Mapp Biopharmaceutical’s ZMapp, Regeneron Pharmaceuticals Inc’s REGN-EB3 and Remdesivir, made by Gilead Sciences, said WHO spokesman Tarik Jasarevic. “The protocols for the fourth being submitted. Logistics underway with MSF support for importation of a few courses about 10 each,” he added in an email. The U.N. health agency has said there have so far been no known cases of Ebola spreading between people in Uganda - all recorded patients had travelled in from Congo. Four experimental therapeutic treatments are already being used in Congo, it added. On Friday, a WHO panel decided not to declare an international emergency over Congo’s Ebola outbreak despite its spread to Uganda, saying such a declaration could cause too much economic harm. “Obviously, the crisis is far from over,” Mark Green, the head of the U.S. Agency for International Development (USAID), told a news conference in Nairobi. Health workers and people who came in contact with infected people began receiving a Merck experimental vaccine in Uganda on Saturday. (This story corrects name of drug in 5th paragraph to REGN-EB3, not Regeneron). Claim: Uganda clears three experimental Ebola treatments, watches for spread.

SOLUTION: Health workers have got the all-clear to use three experimental Ebola treatments in Uganda, a week after the deadly disease spread over the border from Democratic Republic of Congo, authorities said on Tuesday.

PROBLEM: Paragraph: The jury in a Philadelphia court awarded the $8 billion to a man who previously won $680,000 over his claims that it failed to warn that young men using Risperdal could grow breasts. J&J called the sum “grossly disproportionate with the initial compensatory award” and said it was confident it would be overturned. Legal experts agreed that the penalty was likely to be slashed. But the verdict, which helped drive J&J’s shares down 2% on Wednesday, is an example of how public outrage at the pharmaceutical industry for high drug prices has contributed to harsher verdicts against drugmakers accused of wrongdoing in recent years, legal experts said. Outsized penalties awarded by some juries highlight risks in a longstanding strategy by drugmakers such as J&J of taking their chances at trial rather then settle product liability lawsuits brought by patients. “Every pharmaceutical company needs to seriously consider if they want to litigate to verdict in the present environment, but with the settlement demands so incredibly high it’s not always clear what their alternative is,” said Barry Thompson, a partner at Baker McKenzie law firm who was not involved in the case. Drugmakers often prefer to litigate rather than settle in hopes of protecting their brands and discouraging future patient lawsuits, Thompson said. Companies also may use a series of early trial verdicts to gauge the size of any settlement it might eventually offer, as Merck & Co (MRK.N) did with its withdrawn Vioxx arthritis pain drug when facing thousands of lawsuits by patients who claimed harm from the drug. A 2003 U.S. Supreme Court decision suggests that the upper limit of a fair punitive penalty in the Risperdal case would be about $6 million based on the earlier compensatory award. J&J could still get a favorable ruling on appeal that would give the company leverage in dealing with the remaining cases, said Benjamin McMichael, a professor at the Alabama School of Law who has researched punitive damage awards. “With such a large punitive damages award at issue, appellate courts may be more willing to come down hard on the plaintiffs,” McMichael said. J&J faces more than 13,000 lawsuits tied to Risperdal alleging that it caused a condition called gynecomastia in boys, in which breast tissue becomes enlarged. The company is also facing lawsuits involving its baby powder, opioids, medical devices and other products. “We’re operating within a very litigious environment, and we must at times be willing to go to trial when the science, facts and law are on our side,” J&J spokesman Ernie Knewitz said in an email. “We also have to remain open to resolving cases through settlement when and where that’s appropriate to do. We have a proven track record of being able to successfully and appropriately manage this balance,” Knewitz added. The company has had its share of legal wins, losses and settlements. An Oklahoma judge in August ordered J&J to pay $572.1 million to that state for its part in fueling the opioid crisis by deceptively marketing addictive painkillers, although the sum was substantially less than investors had expected. Johnson & Johnson has said it plans to appeal the ruling. Earlier this month, the company agreed to pay $20.4 million to settle claims by two Ohio counties, avoiding a federal opioid trial. In 2013, J&J paid more than $2.2 billion to resolve civil and criminal investigations by the U.S. Department of Justice into its marketing of Risperdal and other drugs. Claim: Massive jury award against J&J highlights risks of its legal strategy.

SOLUTION: A jury award that hit Johnson & Johnson (JNJ.N) with $8 billion in punitive damages for a case involving its anti-psychotic drug Risperdal highlights the risks of the drugmaker’s all-or-nothing legal strategy, several legal experts told Reuters on Wednesday.

PROBLEM: Paragraph: The Fayetteville Observer reports Secretary Robert Wilkie spoke earlier this week about veterans’ mental health during the North Carolina Business Trade Show in Fayetteville. He pointed to the new mental health center being built at the Fayetteville Veterans Affairs Medical Center as evidence of the VA’s commitment to veterans. Officials say the two-story, 15,400 square-foot building is more than 75% complete. Wilkie also says the VA’s same-day mental health services are now available to veterans who received “other than honorable” discharges. Wilkie says about $9.5 billion — or about 10% — of the VA’s budget goes toward mental health services. Claim: Veteran Affairs head discusses mental health aid in NC visit.

SOLUTION:
The secretary of the U.S. Department of Veteran Affairs says the government is making changes to improve mental health services, which he called “the last great medical frontier.”